Compare ACRS & WLKP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | WLKP |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 752.5M |
| IPO Year | 2015 | 2014 |
| Metric | ACRS | WLKP |
|---|---|---|
| Price | $5.17 | $21.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $10.20 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 18.9K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 8.25% |
| EPS Growth | ★ 69.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,683,000.00 | ★ $1,166,695,000.00 |
| Revenue This Year | N/A | $19.48 |
| Revenue Next Year | $4.24 | $5.24 |
| P/E Ratio | ★ N/A | $15.30 |
| Revenue Growth | N/A | ★ 2.71 |
| 52 Week Low | $1.74 | $17.75 |
| 52 Week High | $6.60 | $23.88 |
| Indicator | ACRS | WLKP |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 47.75 |
| Support Level | $4.99 | $21.45 |
| Resistance Level | $5.87 | $22.27 |
| Average True Range (ATR) | 0.36 | 0.31 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 15.38 | 44.26 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products, such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen, to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.